Service d'immuno-oncologie

Equipe principale
Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


113 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 | 2015 | 2014 | 2013 | 2012 | 2006 | 1996 |
Sous presse
 
Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings.
Martin-Quesada A.I., Llabres-Valentí E., Montesdeoca-Godoy C.M., Martín-Abreu C., Alemán-Sánchez C., Rodríguez-Pérez N., Herrero-Márquez A., Cruz-Jurado J., Hernández-Sosa M., Marrero-García M. et al. Clinical & translational oncology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F07A40343CE2]
2024
 
Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome.
Consiglieri G., Tucci F., De Pellegrin M., Guerrini B., Cattoni A., Risca G., Scarparo S., Sarzana M., Pontesilli S., Mellone R. et al., 2024/05. Science translational medicine, 16 (745) pp. eadi8214. Peer-reviewed.
[DOI][Pmid][serval:BIB_347F51481FD7]
 
Thérapie cellulaire CAR-T dans le traitement des maladies auto-immunes [CAR-T therapy for autoimmune diseases]
Alcaraz-Serna A., Porret R., Trueb L., Ribi C., Seebach J., Muller Y.D., 2024/04/03. Revue medicale suisse, 20 (868) pp. 688-693. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FC7F901BBC55]
 
Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia.
Spertini C., Bénéchet A.P., Birch F., Bellotti A., Román-Trufero M., Arber C., Auner H.W., Mitchell R.A., Spertini O., Smirnova T., 2024/03/28. Cell death discovery, 10 (1) p. 157. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7BF16A506AF]
 
Two to tango: engineered T cells against AML.
Arber C., 2024/02/08. Blood, 143 (6) pp. 476-478. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB6AEE5D9C47]
 
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.
Barras D., Ghisoni E., Chiffelle J., Orcurto A., Dagher J., Fahr N., Benedetti F., Crespo I., Grimm A.J., Morotti M. et al., 2024/02/02. Science immunology, 9 (92) pp. eadg7995. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A58DD7E390E0]
 
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y., Kim J.W., Penson R.T., O'Malley D.M., Parkinson C., Roxburgh P., Plummer R., Im S.A., Imbimbo M., Ferguson M. et al., 2024/01/05. Clinical cancer research, 30 (1) pp. 50-62. Peer-reviewed.
[DOI][Pmid][serval:BIB_2FD8B07447B4]
 
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Passweg J.R., Baldomero H., Ansari M., Arber C., Chalandon Y., Daskalakis M., Diepold M., Diesch-Furlanetto T., Duchosal M.A., Gerull S. et al., 2024/01. Hematological oncology, 42 (1) pp. e3241. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3BE6179F7211]
2023
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.
Apostolova P., Kreutmair S., Toffalori C., Punta M., Unger S., Burk A.C., Wehr C., Maas-Bauer K., Melchinger W., Haring E. et al., 2023/10. British journal of haematology, 203 (2) pp. 264-281. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_34E444E517E5]
 
Reductive carboxylation epigenetically instructs T cell differentiation.
Jaccard A., Wyss T., Maldonado-Pérez N., Rath J.A., Bevilacqua A., Peng J.J., Lepez A., Von Gunten C., Franco F., Kao K.C. et al., 2023/09. Nature, 621 (7980) pp. 849-856. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D1AE6E79E2FB]
 
Développements récents en hématologie, Partie 2
Duchosal Michel A., Alberio Lorenzo, Angelillo-Scherrer Anne, Arber Caroline, Balabanov Stefan, Blum Sabine, Bttcher Steffen, Buser Andreas, Cairoli Anne, Chalandon Yves et al., 2023/08/23. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_E9D38C229944]
 
Développements récents en hématologie, Teil 1
Duchosal Michel A., Alberio Lorenzo, Angelillo-Scherrer Anne, Arber Caroline, Balabanov Stefan, Blum Sabine, Bttcher Steffen, Buser Andreas, Cairoli Anne, Chalandon Yves et al., 2023/08/16. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_BEEE6D0FAED7]
 
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.
Rossi A., Aimar G., Audisio M., Bungaro M., Caglio A., Di Liello R., Gamba T., Gargiulo P., Ghisoni E., Lombardi P. et al., 2023/08. European journal of cancer, 189 p. 112920. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9C4030FF425F]
 
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Tuninetti V., Pace L., Ghisoni E., Quarà V., Arezzo F., Palicelli A., Mandato V.D., Geuna E., Cormio G., Biglia N. et al., 2023/07/15. Cancers, 15 (14) p. 3639. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2631A37FECDF]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
Outcomes and endpoints of relevance in gynecologic cancer clinical trials.
Madariaga A., Sanchez-Bayona R., Herrera F.G., Ramirez P.T., González Martín A., 2023/03/06. International journal of gynecological cancer, 33 (3) pp. 323-332. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C322E7412FC8]
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Tuninetti V., Ghisoni E., Pignata S., Picardo E., Raspagliesi F., Andreetta C., Maldi E., Artioli G., Mammoliti S., Zanchi L. et al., 2023/02/06. Cancers, 15 (4) p. 1032. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B33DF593E7E0]
2022
 
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Viscardi G., Tralongo A.C., Massari F., Lambertini M., Mollica V., Rizzo A., Comito F., Di Liello R., Alfieri S., Imbimbo M. et al., 2022/12. European journal of cancer, 177 pp. 175-185. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6FF32E9F7C2B]
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap.
Ghisoni E., Morotti M., Colomer-Lahiguera S., Eicher M., Coukos G., Trueb L., Di Maio M., 2022/12. Journal for immunotherapy of cancer, 10 (12) pp. e006082. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E61BEAAE8B5E]
Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
Camviel Nicolas, Wolf Benita, Croce Giancarlo, Gfeller David, Zoete Vincent, Arber Caroline, 2022/11. Journal for ImmunoTherapy of Cancer, 10 (11) pp. e005091. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F15484E457D0]
Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
Stadelmann Raphael, Cairoli Anne, Arber Caroline, 2022/10/31. healthbook TIMES Oncology Hematology - Edition 3 / 2022 13. Peer-reviewed.
[URN][DOI][serval:BIB_99272140464E]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
2021
 
A knock-in rat model unravels acute and chronic renal toxicity in glutaric aciduria type I.
Gonzalez Melo M., Fontana A.O., Viertl D., Allenbach G., Prior J.O., Rotman S., Feichtinger R.G., Mayr J.A., Costanzo M., Caterino M. et al., 2021/12. Molecular genetics and metabolism, 134 (4) pp. 287-300. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_05A57A99C9CF]
 
Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.
Saghafinia S., Homicsko K., Di Domenico A., Wullschleger S., Perren A., Marinoni I., Ciriello G., Michael I.P., Hanahan D., 2021/10. Cancer discovery, 11 (10) pp. 2638-2657. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E3BABADE6621]
A promising platform for predicting toxicity.
Ochoa de Olza M., 2021/09/24. eLife, 10 pp. e73191. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3B55CEFF0A5A]
Tumor-Associated Microbiome: Where Do We Stand?
Oliva M., Mulet-Margalef N., Ochoa-De-Olza M., Napoli S., Mas J., Laquente B., Alemany L., Duell E.J., Nuciforo P., Moreno V., 2021/02/01. International journal of molecular sciences, 22 (3) p. 1446. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4BC233AA8DB1]
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.
Cachot A., Bilous M., Liu Y.C., Li X., Saillard M., Cenerenti M., Rockinger G.A., Wyss T., Guillaume P., Schmidt J. et al., 2021/02. Science advances, 7 (9) pp. eabe3348. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7FDE10B2A046]
 
Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies.
D'Onofrio A., Gano L., Melo R., Mendes F., Oliveira M.C., Denoël T., Schaefer N., Viertl D., Fierle J., Coukos G. et al., 2021/01. European journal of pharmaceutics and biopharmaceutics, 158 pp. 233-244. Peer-reviewed.
[DOI][Pmid][serval:BIB_95FD98ADDB6D]
 
The use of 68Ga-EDTA PET allows detecting progressive decline of renal function in rats.
Fontana A.O., Gonzalez Melo M., Allenbach G., Georgantas C., Wang R., Braissant O., Barbey F., Prior J.O., Ballhausen D., Viertl D., 2021. American journal of nuclear medicine and molecular imaging, 11 (6) pp. 519-528. Peer-reviewed.
[WoS][Pmid][serval:BIB_A42CB7293042]
2020
 
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon P.O., Harari A., Auger A., Murgues C., Zangiacomi V., Rubin O., Ellefsen Lavoie K., Guillemot L., Navarro Rodrigo B., Nguyen-Ngoc T. et al., 2020/12. Cytotherapy, 22 (12) pp. 780-791. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30851676B0A7]
Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes
Chong Chloe, Müller Markus, Pak HuiSong, Harnett Dermot, Huber Florian, Grun Delphine, Leleu Marion, Auger Aymeric, Arnaud Marion, Stevenson Brian J. et al., 2020/12. Nature Communications, 11 (1). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_03EA897A1141]
 
Structural dissimilarity from self drives neoepitope escape from immune tolerance.
Devlin J.R., Alonso J.A., Ayres C.M., Keller GLJ, Bobisse S., Vander Kooi C.W., Coukos G., Gfeller D., Harari A., Baker B.M., 2020/11. Nature chemical biology, 16 (11) pp. 1269-1276. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_186F0AD1C570]
Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells.
Bajwa G., Lanz I., Cardenas M., Brenner M.K., Arber C., 2020/11. Journal for immunotherapy of cancer, 8 (2) pp. e001487. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FD8350547BA6]
 
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.
Wells D.K., van Buuren M.M., Dang K.K., Hubbard-Lucey V.M., Sheehan KCF, Campbell K.M., Lamb A., Ward J.P., Sidney J., Blazquez A.B. et al., 2020/10/29. Cell, 183 (3) pp. 818-834.e13. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F6095670EC38]
 
Survival of the fetus: cervical cancer and pregnancy, a challenging combination.
Levy L., Meuwly J.Y., Sarivalasis A., Achtari C., Mathevet P., Herrera F.G., 2020/09/05. Lancet, 396 (10252) p. 725. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_16AC5A00A805]
 
High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays.
Brandenberg N., Hoehnel S., Kuttler F., Homicsko K., Ceroni C., Ringel T., Gjorevski N., Schwank G., Coukos G., Turcatti G. et al., 2020/09. Nature biomedical engineering, 4 (9) pp. 863-874. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_71E34713FAA0]
 
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development.
Ochoa de Olza M., Navarro Rodrigo B., Zimmermann S., Coukos G., 2020/09. The Lancet. Oncology, 21 (9) pp. e419-e430. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_208B57498352]
 
<sup>177</sup>Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma.
Delage J.A., Faivre-Chauvet A., Fierle J.K., Gnesin S., Schaefer N., Coukos G., Dunn S.M., Viertl D., Prior J.O., 2020/08/17. EJNMMI research, 10 (1) p. 98. Peer-reviewed.
[DOI][Pmid][serval:BIB_4E04534CDA56]
 
Correction to: Preclinical Evaluation and Dosimetry of [111In] CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1)
Cicone Francesco, Denoël Thibaut, Gnesin Silvano, Riggi Nicolo, Irving Melita, Jakka Gopinadh, Schaefer Niklaus, Viertl David, Coukos George, Prior John O., 2020/08. 1.
[DOI][WoS][Pmid][serval:BIB_81A7D3CC3803]
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A., Hottinger A., Wolf B., Navarro Rodrigo B., Ochoa de Olza M., Auger A., Kuntzer T., Comte D., Zimmer V., Gannon P. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e001155. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C930B13A53AD]
Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1).
Cicone F., Denoël T., Gnesin S., Riggi N., Irving M., Jakka G., Schaefer N., Viertl D., Coukos G., Prior J.O., 2020/08. Molecular imaging and biology, 22 (4) pp. 979-991. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_813B48F40C5F]
 
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams S.F., Grimm A.J., Chiang C.L., Mookerjee A., Flies D., Jean S., McCann G.A., Michaux J., Pak H., Huber F. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e000875. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B7CF92C7BCB]
 
Multielemental Analysis of Low-Volume Samples Reveals Cancer-Specific Profile in Serum and Sorted Immune Cells
Konz Tobias, Monnard Caroline, Restrepo Marcela Rincon, Laval Julie, Sizzano Federico, Girotra Mukul, Dammone Gabriele, Palini Alessio, Coukos George, Rezzi Serge et al., 2020/07/07. Analytical Chemistry, 92 (13) pp. 8750-8758.
[DOI][Pmid][serval:BIB_3A58DA889942]
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4<sup>+</sup> T cells.
Rath J.A., Bajwa G., Carreres B., Hoyer E., Gruber I., Martínez-Paniagua M.A., Yu Y.R., Nouraee N., Sadeghi F., Wu M. et al., 2020/07. Science advances, 6 (27) pp. eaaz7809. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D26F38B87AE4]
 
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Wyss T., Inoges S., de Vries IJM, Dartiguenave F., Jichlinski P., Derrè L., Coukos G. et al., 2020/06/23. European journal of cancer, 135 pp. 173-182. Peer-reviewed.
[DOI][Pmid][serval:BIB_2DED61B64BB4]
 
Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma.
Dheilly E., Battistello E., Katanayeva N., Sungalee S., Michaux J., Duns G., Wehrle S., Sordet-Dessimoz J., Mina M., Racle J. et al., 2020/05/11. Cancer cell, 37 (5) pp. 674-689.e12. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C0FB07A8B571]
 
Immune Therapy Opportunities in Ovarian Cancer.
Kandalaft L.E., Odunsi K., Coukos G., 2020/05. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 40 pp. 1-13. Peer-reviewed.
[DOI][Pmid][serval:BIB_71D55C2B15BF]
Oncologie : naviguer la pandémie de COVID-19 et garder le cap [Oncology: navigating the COVID-19 Pandemic and Steer the Course]
Zimmermann S., Dietrich P.Y., Michielin O., Betticher D., Peters S., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 819-822. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0B2FC89C06E5]
 
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.
Giordano-Attianese G., Gainza P., Gray-Gaillard E., Cribioli E., Shui S., Kim S., Kwak M.J., Vollers S., Corria Osorio A.J., Reichenbach P. et al., 2020/04. Nature biotechnology, 38 (4) pp. 426-432. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EBAD72E3D84D]
miR-155 Overexpression in OT-1 CD8<sup>+</sup> T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen.
Monnot G.C., Martinez-Usatorre A., Lanitis E., Lopes S.F., Cheng W.C., Ho P.C., Irving M., Coukos G., Donda A., Romero P., 2020/03/27. Molecular therapy oncolytics, 16 pp. 111-123. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_39DC24C5C585]
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi L., Vitale I., Warren S., Adjemian S., Agostinis P., Martinez A.B., Chan T.A., Coukos G., Demaria S., Deutsch E. et al., 2020/03. Journal for immunotherapy of cancer, 8 (1) pp. e000337. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_56620B5927E2]
European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows.
Passaro A., Mackenzie G., Lambertini M., Morgan G., Zimmermann S., Garrido P., Curigliano G., Trapani D., 2020/02. ESMO open, 5 (1) pp. e000598. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5A52E3E1E643]
 
Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands.
Solleder M., Guillaume P., Racle J., Michaux J., Pak H.S., Müller M., Coukos G., Bassani-Sternberg M., Gfeller D., 2020/02. Molecular & cellular proteomics, 19 (2) pp. 390-404. Peer-reviewed.
[DOI][Pmid][serval:BIB_0EBACC6764B1]
Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ.
Germann M., Zangger N., Sauvain M.O., Sempoux C., Bowler A.D., Wirapati P., Kandalaft L.E., Delorenzi M., Tejpar S., Coukos G. et al., 2020/01/09. EMBO molecular medicine, 12 (1) pp. e10681. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F06A8D6CE8D2]
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure.
Vigano S., Bobisse S., Coukos G., Perreau M., Harari A., 2020. Frontiers in immunology, 11 p. 1350. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_19C82F6CB34E]
Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C., Gruber I., Arber C., 2020. Frontiers in immunology, 11 p. 583716. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_812C7CDE2860]
 
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F., Schiappacasse L., Levivier M., Tuleasca C., Cuendet M.A., Aedo-Lopez V., Gautron Moura B., Homicsko K., Bettini A., Berthod G. et al., 2020/01. Journal of neuro-oncology, 146 (1) pp. 181-193. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_18BD1C202E95]
2019
 
Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry.
Girotra M., Thierry A.C., Harari A., Coukos G., Naveiras O., Vannini N., 2019/12/26. Journal of visualized experiments 154. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DE9A27B5B4E4]
Microfluidic device performing on flow study of serial cell-cell interactions of two cell populations.
Duchamp M., Dahoun T., Vaillier C., Arnaud M., Bobisse S., Coukos G., Harari A., Renaud P., 2019/12/09. RSC advances, 9 (70) pp. 41066-41073. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E280C4A083E]
Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg
Peisl Sarah, Zimmermann Stefan, Camey Bertrand, Betticher Daniel, Bouchardy Christine, 2019/12. BMC Cancer, 19 (1).
[URN][DOI][Pmid][serval:BIB_404FE0B9834F]
 
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U., Michielin O., Lluesma S.M., Tsourti Z., Polydoropoulou V., Karlis D., Besser M.J., Haanen J., Svane I.M., Ohashi P.S. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1902-1913. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DF9E566FB280]
 
Gender medicine and oncology: report and consensus of an ESMO workshop.
Wagner A.D., Oertelt-Prigione S., Adjei A., Buclin T., Cristina V., Csajka C., Coukos G., Dafni U., Dotto G.P., Ducreux M. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1914-1924. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7C76EA90383]
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A., Boudousquié C., Balint K., Stevenson B.J., Gannon P.O., Iancu E.M., Rossier L., Martin Lluesma S., Mathevet P., Sempoux C. et al., 2019/11/26. Journal of translational medicine, 17 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_313F7CD9FDBC]
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A., Griffiths B., Michaux J., Pak H.S., Stevenson B.J., Woolston A., Semiannikova M., Spain G., Barber L.J., Matthews N. et al., 2019/11/18. Journal for immunotherapy of cancer, 7 (1) p. 309. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7418AE3DFDA7]
 
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.
Racle J., Michaux J., Rockinger G.A., Arnaud M., Bobisse S., Chong C., Guillaume P., Coukos G., Harari A., Jandus C. et al., 2019/11. Nature biotechnology, 37 (11) pp. 1283-1286. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9A8D08A5BC6]
 
The Romand Network of Oncology: bridging the gap of personalised oncology
Michielin O., Tsantoulis P., Homicsko K., Christinat Y., De Leval L., Bisig B., Missiaglia E., Zoete V., Krebs F., Fortin A. et al., 2019/10/18. Swiss Medical Weekly.
[serval:BIB_2A3947B3BCE2]
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8<sup>+</sup> T cells.
Mastelic-Gavillet B., Navarro Rodrigo B., Décombaz L., Wang H., Ercolano G., Ahmed R., Lozano L.E., Ianaro A., Derré L., Valerio M. et al., 2019/10/10. Journal for immunotherapy of cancer, 7 (1) p. 257. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC3C085DEA43]
 
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade.
Zimmermann S., Peters S., 2019/10/01. JAMA oncology, 5 (10) pp. 1403-1405. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4DB804EB26DC]
Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery.
Fierle J.K., Abram-Saliba J., Brioschi M., deTiani M., Coukos G., Dunn S.M., 2019/09/06. Scientific reports, 9 (1) p. 12815. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FCB67A02E15F]
 
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y. et al., 2019/09. Nature reviews. Clinical oncology, 16 (9) pp. 563-580. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F8DDEE8DA1E]
 
Current Diagnosis and Management of Small-Cell Lung Cancer.
Wang S., Zimmermann S., Parikh K., Mansfield A.S., Adjei A.A., 2019/08. Mayo Clinic proceedings, 94 (8) pp. 1599-1622. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AA5A2D533FC4]
 
F-18-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Jreige M., Letovanec I., Chaba K., Renaud S., Rusakiewicz S., Cristina V., Peters S., Krueger T., de Leval L., Kandalaft L.E. et al., 2019/08. European journal of nuclear medicine and molecular imaging, 46 (9) pp. 1859-1868. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F575C6723CE]
Rational combinations of immunotherapy with radiotherapy in ovarian cancer.
Herrera F.G., Irving M., Kandalaft L.E., Coukos G., 2019/08. The Lancet. Oncology, 20 (8) pp. e417-e433. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B919A825548B]
 
High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.
Costa-Nunes C., Cachot A., Bobisse S., Arnaud M., Genolet R., Baumgaertner P., Speiser D.E., Sousa Alves P.M., Sandoval F., Adotévi O. et al., 2019/07/15. Clinical cancer research, 25 (14) pp. 4320-4331. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_99ED3D648751]
Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E., Imbimbo M., Zimmermann S., Valabrega G., 2019/06/15. International journal of molecular sciences, 20 (12). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_95BDEE5B335B]
Effets indésirables des inhibiteurs de points de contrôle immunitaire : diagnostic et prise en charge [Side effects of immune checkpoint inhibitors: diagnosis and management]
Perrinjaquet C., Zaher M., Ferraro D.A., Comte D., Trueb L., Zimmermann S., Coukos G., Orcurto A., 2019/05/15. Revue medicale suisse, 15 (651) pp. 1010-1016. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_542B193CD99A]
 
Tumor Landscapes: β-Catenin Drives Immune Desertification.
Dangaj D., Barras D., Coukos G., 2019/05/15. Clinical cancer research, 25 (10) pp. 2943-2945. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7529A1E77088]
 
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.
Zimmerman S., Das A., Wang S., Julian R., Gandhi L., Wolf J., 2019/05. Journal of thoracic oncology, 14 (5) pp. 768-783. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9E57E859D95D]
 
Progrès récents et orientations futures de la thérapie avec cellules CAR-T en oncologie pédiatrique [Recent advances and future directions in CAR-T cell therapy in pediatric oncology]
Ceppi F., Renella R., Diezi M., Ansari M., Duchosal M.A., Arber C., Kandalaft L., Coukos G., Beck-Popovic M., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 85-91. Peer-reviewed.
[Pmid][serval:BIB_556228939270]
Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands.
Perez MAS, Bassani-Sternberg M., Coukos G., Gfeller D., Zoete V., 2019. Frontiers in immunology, 10 p. 2731. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA3DEC8F83B0]
 
La médecine personnalisée en oncologie dans: Médecine Personnalisée
Colomer-Lahiguera S., Coukos G., Peters S., Kandalaft L., Michielin O., Eicher M., 2019. dans Médecine Personnalisée, Académie Suisse de Sciences Médicales.
[serval:BIB_B2FAEFC8A271]
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F., Sykiotis G.P., Maillard M., Fraga M., Ribi C., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F. et al., 2019/01. The Lancet. Oncology, 20 (1) pp. e54-e64. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_42DB9145A8A7]
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S., Alatzoglou D., Irving M., Ménétrier-Caux C., Caux C., Romero P., Coukos G., 2019. Frontiers in immunology, 10 p. 925. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E661607B7DC8]
2018
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
Horisberger A., La Rosa S., Zurcher J.P., Zimmermann S., Spertini F., Coukos G., Obeid M., 2018/12/27. Journal for immunotherapy of cancer, 6 (1) p. 156. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BD7EE077DFE6]
 
Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC.
Zimmermann S., Peters S., 2018/09. Journal of thoracic oncology, 13 (9) pp. 1242-1244. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_523AAD462218]
 
Computational design of orthogonal membrane receptor-effector switches for rewiring signaling pathways.
Young M., Dahoun T., Sokrat B., Arber C., Chen K.M., Bouvier M., Barth P., 2018/07/03. Proceedings of the National Academy of Sciences of the United States of America, 115 (27) pp. 7051-7056. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8C56DD9E0F4C]
 
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S., Zimmermann S., 2018/05/28. Current treatment options in oncology, 19 (7) p. 37. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5AE72E5CA1C1]
 
Immune Checkpoint Inhibitors in the Management of Lung Cancer.
Zimmermann S., Peters S., Owinokoko T., Gadgeel S.M., 2018/05/23. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 38 pp. 682-695. Peer-reviewed.
[DOI][Pmid][serval:BIB_07DB0A3C900D]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
[DOI][WoS][Pmid][serval:BIB_641968BB356B]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi J.L., Bobisse S., Ophir E., Tuyaerts S., Roberti A., Genolet R., Baumgartner P., Stevenson B.J., Iseli C., Dangaj D. et al., 2018/04/11. Science translational medicine, 10 (436) pp. NA. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBC10D090AEF]
 
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Neubert N.J., Schmittnaegel M., Bordry N., Nassiri S., Wald N., Martignier C., Tillé L., Homicsko K., Damsky W., Maby-El Hajjami H. et al., 2018/04/11. Science translational medicine, 10 (436). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE6933D4F057]
Correction to: CART cells are prone to Fas- and DR5-mediated cell death.
Tschumi B.O., Dumauthioz N., Marti B., Zhang L., Lanitis E., Irving M., Schneider P., Mach J.P., Coukos G., Romero P. et al., 2018. Journal for Immunotherapy of Cancer, 6 (1) p. 92. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AE20F9B96389]
 
L’immunothérapie cellulaire adoptive arrive en Suisse : de nouveaux ou-TIL-s pour combattre le cancer. Onkologiepflege, Nr. 1-2018 (2018).
Colomer-Lahiguera Sara, Debarge Patricia, Serena Andrea, Trueb Lionel, Eicher Manuela, George Coukos, 2018..
[serval:BIB_1C5819F94372]
2016
Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
Ngo-Giang-Huong N., Wittkop L., Judd A., Reiss P., Goetghebuer T., Duiculescu D., Noguera-Julian A., Marczynska M., Giacquinto C., Ene L. et al., 2016/11/08. BMC infectious diseases, 16 (1) p. 654. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E1EBE8BEC65]
 
Scientific Advances in Lung Cancer 2015.
Tsao A.S., Scagliotti G.V., Bunn P.A., Carbone D.P., Warren G.W., Bai C., de Koning H.J., Yousaf-Khan A.U., McWilliams A., Tsao M.S. et al., 2016/05. Journal of thoracic oncology, 11 (5) pp. 613-638. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_02E8A7A685FB]
 
Lung Cancer
Zimmermann Stefan, Peters Solange, Dziadziuszko Rafal, Baumann Michael, Mitsudomi Tetsuya, Kerr Keith K., 2016/01. dans Kerr David J., Haller Daniel G., van der Velde Cornelis J. H., Baumann Michael, Nagahiro Saijo (eds.) Oxford Textbook of Oncology, Oxford University Press.
[DOI][serval:BIB_B8EC9148BA62]
 
Seeking New Approaches to Patients With Small Cell Lung Cancer
Pietanza Marie Catherine, Zimmermann Stefan, Peters Solange, Curran Walter J., 2016. pp. e477-e482 dans American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology (ASCO).
[DOI][Pmid][serval:BIB_85C3502DCC98]
2015
 
Immuno-Oncology
Michielin Olivier, Coukos George, 2015/09/09. Progress in Tumor Research, 42, S. Karger AG.
[DOI][serval:BIB_3BABB0481053]
 
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer.
Zimmermann S., Peters S., 2015. Cancer Metastasis Reviews, 34 (2) pp. 173-182. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_144BD877A6B1]
 
Targeting Programmed Cell Death 1 in Ovarian Cancer.
Homicsko K., Coukos G., 2015. Journal of Clinical Oncology, 33 (34) pp. 3987-3989. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A88FF3F32E5C]
2014
 
A community computational challenge to predict the activity of pairs of compounds.
Bansal M., Yang J., Karan C., Menden M.P., Costello J.C., Tang H., Xiao G., Li Y., Allen J., Zhong R. et al., 2014/12. Nature biotechnology, 32 (12) pp. 1213-1222. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F647C6B32994]
 
A community effort to assess and improve drug sensitivity prediction algorithms.
Costello J.C., Heiser L.M., Georgii E., Gönen M., Menden M.P., Wang N.J., Bansal M., Ammad-ud-din M., Hintsanen P., Khan S.A. et al., 2014/12. Nature biotechnology, 32 (12) pp. 1202-1212. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_71822A472839]
 
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S., Zimmermann Stefan, Adjei A.A., 2014/09. Cancer treatment reviews, 40 (8) pp. 917-926. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7DD2E25A4F89]
 
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Zimmermann Stefan, Dziadziuszko R., Peters S., 2014/07. Cancer treatment reviews, 40 (6) pp. 716-722. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C4DDFE5880FE]
 
Targeted therapy in NSCLC driven by HER2 insertions.
Peters S., Zimmermann Stefan, 2014/04. Translational lung cancer research, 3 (2) pp. 84-88. Peer-reviewed.
[DOI][Pmid][serval:BIB_2D90386853EE]
 
Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer.
Voide C., Zimmermann Stefan, Adjei A.A., Betticher D.C., Meuli R., Prod'hom G., Giulieri S., Peters S., 2014/03. Journal of thoracic oncology, 9 (3) pp. e24-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_77173EE42F11]
2013
 
Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer.
Zimmermann Stefan, Peters S., 2013/09. EJC supplements, 11 (2) pp. 307-309. Peer-reviewed.
[DOI][Pmid][serval:BIB_9935D0603744]
 
Lung Cancer
Zimmermann Stefan, Curioni Fontecedro Alessandra, Stahel Rolf, Peters Solange, 2013. dans DiCato Mario (eds.) Side Effects of Medical Cancer Therapy, Springer London.
[DOI][serval:BIB_271E913B0CF2]
2012
Going beyond EGFR
Zimmermann S., Peters S., 2012/09/01. Annals of Oncology, 23 (suppl 10) pp. x197-x203.
[URN][DOI][WoS][Pmid][serval:BIB_27744B6D18C2]
 
Severe peritonitis induced by methotrexate during treatment of persistent gestational trophoblastic disease.
Zimmermann Stefan, Zaman K., Wolfer A., Jacot W., 2012. The oncologist, 17 (8) pp. e18-20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9F215F319AC7]
2006
 
Equilibre acido-basique
Trueb Lionel, Albrecht Eric, 2006/09/01. pp. 389-393 dans Manuel pratique d'anesthésie, Masson.
[serval:BIB_850002C1B688]
 
Troubles électrolytiques
Trueb Lionel, Albrecht Eric, 2006/09/01. pp. 381-388 dans Manuel pratique d'anesthésie, Masson.
[serval:BIB_731A330459B0]
1996
 
Sympathetic-nerve activity before and after resection of an insulinoma
Scherrer U., Owlya R., Trueb L., 1996/10. New England Journal of Medicine, 335 (16) pp. 1240-2.
[DOI][WoS][Pmid][serval:BIB_0AB42D5204E4]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University